Connection

Bonaventura Clotet to RNA, Viral

This is a "connection" page, showing publications Bonaventura Clotet has written about RNA, Viral.
Connection Strength

0.117
  1. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. J Antimicrob Chemother. 2018 03 01; 73(3):732-737.
    View in: PubMed
    Score: 0.025
  2. Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death. PLoS One. 2017; 12(1):e0166613.
    View in: PubMed
    Score: 0.024
  3. Functional analyses reveal extensive RRE plasticity in primary HIV-1 sequences selected under selective pressure. PLoS One. 2014; 9(8):e106299.
    View in: PubMed
    Score: 0.020
  4. Pigs are not susceptible to SARS-CoV-2 infection but are a model for viral immunogenicity studies. Transbound Emerg Dis. 2021 Jul; 68(4):1721-1725.
    View in: PubMed
    Score: 0.008
  5. Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. Ann Intern Med. 2018 11 20; 169(10):674-683.
    View in: PubMed
    Score: 0.007
  6. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV. 2018 11; 5(11):e638-e646.
    View in: PubMed
    Score: 0.007
  7. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. J Antimicrob Chemother. 2018 07 01; 73(7):1965-1971.
    View in: PubMed
    Score: 0.006
  8. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. J Antimicrob Chemother. 2018 07 01; 73(7):1940-1948.
    View in: PubMed
    Score: 0.006
  9. Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy. Virol J. 2013 Dec 05; 10:350.
    View in: PubMed
    Score: 0.005
  10. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment. Antivir Ther. 2010; 15(3):333-42.
    View in: PubMed
    Score: 0.004
  11. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. Virus Res. 2008 Feb; 131(2):260-70.
    View in: PubMed
    Score: 0.003
  12. Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. J Antimicrob Chemother. 2005 Jun; 55(6):824-7.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.